Abbott study shows majority of arthritis patients respond to Humira

By Angela McDaniels

Seattle, Nov. 14 - Abbott Laboratories said preliminary data show 61% of rheumatoid arthritis patients taking Humira showed a clinical response and one-third experienced a 50% or greater improvement in signs and symptoms.

The data was part of a 12-week study that included 6,610 patients with rheumatoid arthritis who failed previous therapy with other anti-tumor necrosis factor treatments.

Patients at 450 sites in 11 European countries and Australia were given 40 milligrams of Humira every other week in addition to or as a replacement for pre-existing therapy.

The data will be presented at the American College of Rheumatology annual meeting in San Diego.

In October, Abbott received U.S. Food and Drug Administration approval to market Humira as a first-line treatment for recent-onset moderate to severe rheumatoid arthritis.

Abbott is based in Abbott Park, Ill., and develops pharmaceuticals and medical device products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.